Biocorrx (OTCMKTS:BICX – Get Free Report) is anticipated to issue its resultson Monday, August 17th. Analysts expect the company to post earnings of ($0.05) per share and revenue of $0.24 million for the quarter.
Biocorrx (OTCMKTS:BICX – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.22 million.
Biocorrx Stock Performance
Biocorrx stock opened at $0.30 on Monday. The stock has a market cap of $8.84 million, a PE ratio of -1.86 and a beta of 0.19. Biocorrx has a one year low of $0.20 and a one year high of $1.28. The stock has a fifty day moving average of $0.33 and a 200 day moving average of $0.35.
Biocorrx Company Profile
BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.
Featured Stories
- Five stocks we like better than Biocorrx
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
